Adjuvant gefitinib does not significantly improve overall survival relative to vinorelbine plus cisplatin in patients with completely resected stage II–IIIA, EGFR -mutant non-small-cell lung cancer, final data from the ADJUVANT-CTONG1104 trial show.

Chemotherapy-naïve patients with nonsquamous non-small-cell lung cancer and EGFR -activating mutations derive prolonged progression-free survival from the addition of apatinib to gefitinib, phase 3 ACTIVE data show.

Combining osimertinib with gefitinib has promising efficacy and tolerability in treatment-naïve patients with metastatic EGFR -mutated non-small-cell lung cancer, suggest early data presented at the virtual 2020 ASCO Annual Meeting.

Phase III study results suggest gefitinib in combination with chemotherapy improves outcomes versus gefitinib alone in patients with EGFR -mutated, advanced non-small-cell lung cancer.

Supplementing the EGFR–tyrosine kinase inhibitor gefitinib with pemetrexed and carboplatin doubles progression-free survival in patients with advanced, chemotherapy-naïve non-small-cell lung cancer harboring activating EGFR mutations, according to phase III results.

Non-small-cell lung cancer patients with acquired resistance to epidermal growth factor receptor–tyrosine kinase inhibitor therapy and MET dysregulation could benefit from the addition of the MET inhibitor capmatinib to gefitinib, early results suggest.

Adjuvant gefitinib could offer an alternative to cisplatin-based adjuvant chemotherapy for patients with completely resected stage II–IIIA, EGFR -mutant non-small-cell lung cancer, according to the findings of a phase III trial.

The objective response rate was comparable between the dacomitinib and gefitinib trial arms (74.9 and 71.6%, respectively), but the duration of response was significantly longer with the second-generation EGFR tyrosine kinase inhibitor, at a median of 14.8 months compared with 8.3 months for gefitinib.

He added that combining the MET inhibitor tepotinib with the EGFR–tyrosine kinase inhibitor gefitinib showed clinical activity in this patient population in the INSIGHT study  leading the authors to investigate tepotinib plus osimertinib in INSIGHT 2.

First-line treatment with the third-generation EGFR–tyrosine kinase inhibitor aumolertinib significantly improves progression-free survival relative to gefitinib in people with advanced non-small-cell lung cancer and sensitizing EGFR mutations, indicate Chinese trial data.

The analysis included data on 168 patients (89 with NSCLC, 79 with melanoma) who received first-line TKI therapy with dabrafenib, vemurafenib, gefitinib, afatinib, or erlotinib between January 2015 and April 2017 at The Christie NHS Foundation Trust.

Afatinib was the most commonly used EGFR–TKI in this group (46% of 79 treatments), followed by erlotinib (28%), gefitinib (16%), and osimertinib (10%), and median PFS differed significantly by treatment.

Arrieta and colleagues point out that the primary results of the phase 2 study  are in contrast to those of another trial of metformin plus gefitinib in diabetes-free Chinese patients with advanced EGFR mutation-positive NSCLC, which showed no improvement in PFS or OS with metformin addition.

All patients included in the current report had previously been treated with EGFR– or pan-HER–TKIs (such as gefitinib, osimertinib, and afatinib), and three had a single G719X mutation, while the remaining seven patients additionally harbored at least one other EGFR mutation, such as S768I and T790M.

The FLAURA trial comparing osimertinib with erlotinib or gefitinib in the first-line treatment of EGFR -mutated, advanced non-small-cell lung cancer has shown positive overall survival results favoring the third-generation EGFR–tyrosine kinase inhibitor.

FLAURA is a phase III trial pitting the third-generation EGFR–tyrosine kinase inhibitor osimertinib against gefitinib or erlotinib for the first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer.

The FoundationOne Liquid CDx (Foundation Medicine Inc, Cambridge, Massachusetts, USA) has been approved as a companion diagnostic test for identification of EGFR exon 19 deletions and exon 21 L858R alterations for use of gefitinib, osimertinib, and erlotinib in patients with non-small-cell lung cancer.

Julia Rotow outlines the rationale and preliminary findings of a study of concurrent osimertinib and gefitinib for treatment-naïve EGFR -mutated non-small-cell lung cancer (6:59).

Suresh Ramalingam presents the overall survival analysis of the FLAURA trial of osimertinib in EGFR mutation-positive, advanced non-small-cell lung cancer, and discusses the options after progression on the tyrosine kinase inhibitor (1:50).

Their phase I trial enrolled individuals who had developed resistance to erlotinib, gefitinib, or afatinib – but were negative for the EGFR T790M mutation – or had progressed on osimertinib.